-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utomilumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utomilumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utomilumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Utomilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mecbotamab Vedotin in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mecbotamab Vedotin in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mecbotamab Vedotin in Breast Cancer Drug Details: BA-3011 is under development...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewLeptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2024
Empower your strategies with our Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) – Drugs In Development, 2024 report and make more profitable business decisions. Leptomeningeal carcinomatosis is a condition involving the infiltration of cancer into the protective layers of the brain, specifically the pia mater and arachnoid mater. Solid tumors, notably breast, lung, melanoma, gastrointestinal, and primary central nervous system tumors, can give rise to leptomeningeal carcinomatosis. Cancer cells may reach the leptomeninges through various routes, such as direct seeding from brain...
-
Product Insights
NewEpendymoma – Drugs In Development, 2024
Empower your strategies with our Ependymoma – Drugs In Development, 2024 report and make more profitable business decisions. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms...
-
Product Insights
NewHairy Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our Hairy Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness, and weight loss. Risk factors include exposure to radiation, chemicals, and saw dust. Treatment includes surgery, chemotherapy, and radiation therapy. The Hairy Cell...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...
-
Product Insights
NewBurkitt Lymphoma – Drugs In Development, 2024
Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in...